SCHEMBL25979467

SCHEMBL25979467

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc4c(c3)oc3cc(N(c5ccc6ccccc6c5)c5ccc6ccccc6c5)ccc34)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.41
KMT2A Q03164 7/20 0.41
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
CYP1A2 P05177 4/20 0.41
KDM4E B2RXH2 3/20 0.41
HSD17B10 Q99714 3/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 5/20 0.36
HPGD P15428 4/20 0.36
CYP3A4 P08684 3/20 0.34
CYP2C9 P11712 3/20 0.34
RECQL P46063 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 2/20 0.34
LMNA P02545 2/20 0.34
GLA P06280 2/20 0.34
TSHR P16473 2/20 0.34
NPC1 O15118 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25979483 0.97 MEN1 (0.40) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL25979457 0.97 MEN1 (0.40) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL26779230 0.95 MEN1 (0.40) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL26779239 0.95 MEN1 (0.40) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL26779281 0.94 ALDH1A1 (0.42) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL25979783 0.94 ALDH1A1 (0.42) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL25979640 0.94 ALDH1A1 (0.39) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL25978681 0.94 ALDH1A1 (0.39) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL25979930 0.92 CYP1A2 (0.41) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL24255842 0.92 ALDH1A1 (0.38) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
EP-4227301-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 MEN1 257/4885KMT2A 758/4885ALDH1A1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.